skip to Main Content
 

Pfizer: do issues with Paxlovid mean it is still a buy?

*

Pfizer [NYSE:PFE] raised its sales forecast for its Covid-19 vaccine this week by $2bn and told investors that the sale of other drugs has helped it to offset the impact of a strong dollar. But some analysts are not enthusiastic about the booster opportunity from its vaccines. The market liked the results, with shares up over 4% in the five days going into Tuesday's US trading session.

In this article we run the numbers through our AI engine and also get some independent feedback on the strength of its drugs offering as we go into the next quarter. Should investors in Pfizer stock be keeping faith or has most of the upside been undermined by the dollar now?


Want the full story? Access all of The Armchair Trader's content for just £5.99 per month.

Get weekly investment ideas and tips that will take your investing to the next level. Sign up here.

Free 28 day trial. Cancel anytime.


Log In or Sign Up to Armchair Trader+

Already a member? Log in here:


Not a member yet? Sign up for your free trial or check out the benefits of membership.

Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader Plus+ for further details on the benefits of becoming a member.

Like this article? Sign up to our free newsletter.

This article does not constitute investment advice. Do your own research or consult a professional advisor.

The Armchair Trader's 'How to' Guides

In-depth Reports

Detailed reviews of selected companies and investment trusts.

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

Aquis
FP Markets
IG
Pepperstone
WisdomTree
CME Group
Back To Top